Trial Profile

A Phase 1a single ascending dose study of VY-TAU01 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VY TAU01 (Primary)
Indications Alzheimer's disease
Focus Adverse reactions

Most Recent Events

03 Mar 2025 According to a Voyager Therapeutics media release, the company expects to present additional data from the SAD study at an upcoming scientific conference.
03 Mar 2025 Results presented in a Voyager Therapeutics media release.
06 Aug 2024 According to a Voyager Therapeutics media release, company expects top-line safety and pharmacokinetic data from the ongoing SAD trial in first half of 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com